Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI scan could spare thousands from unnecessary kidney surgery

NCT ID NCT07173140

Diagnosis Sponsor: University College, London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether new types of MRI scans can tell the difference between aggressive and harmless kidney tumors before surgery. Currently, standard scans can find tumors but can't tell if they are dangerous. 30 adults with small kidney tumors will get an extra MRI before their planned surgery. The goal is to see if the new MRI can accurately identify which tumors need treatment, potentially avoiding unnecessary surgery for benign ones.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MRI scan with novel sequences
What this could lead to
If successful, this could lead to a non-invasive way to identify which kidney tumors need treatment and which can be safely monitored.
What could go wrong
This is a very small pilot study (30 people) testing a new imaging technique. It may not prove accurate enough to replace biopsies, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Nov 2024

Expected to finish

Sep 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 and over 2. Confirmed renal tumour ≤ 7 cm planned for surgical resection 3. Willing and able to provide written informed consent 4. Able to lie supine for the duration of an MRI Exclusion Criteria: 1. Contraindication to MRI e.g., cardiac pacemaker 2. Contraindication to MR contrast agents 3. Pregnancy 4. Breastfeeding 5. Deranged renal function (eGFR \<30) in the last three months. 6. Previous treatment of the renal tumour e.g., ablation, radiotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney cancers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

kidney cancer kidney neoplasm renal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney cancers MRI Renal cancer Small renal mass

Contacts and locations

Locations

  • University College London

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.